A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI.

MLA

Kim, Kyu-Pyo, et al. “A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI.” Oncology, vol. 88, no. 3, Feb. 2015, pp. 164–72. EBSCOhost, https://doi.org/10.1159/000368674.

APA

Kim, K.-P., Hong, Y. S., Lee, J.-L., Bae, K. S., Kim, H.-S., Shin, J.-G., Lee, J. S., & Kim, T. W. (2015). A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology, 88(3), 164–172. https://doi.org/10.1159/000368674

Chicago

Kim, Kyu-Pyo, Yong Sang Hong, Jae-Lyun Lee, Kyun Seop Bae, Ho-Sook Kim, Jae-Gook Shin, Jung Shin Lee, and Tae Won Kim. 2015. “A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI.” Oncology 88 (3): 164–72. doi:10.1159/000368674.